Health Care(IN00392.US)

18:35 ET Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Rosen Law Firm is investigating potential securities claims for Alvotech (NASDAQ: ALVO) shareholders due to allegations of misleading business information. Investors who purchased Alvotech securities may be eligible for compensation through a class action lawsuit. Following a negative FDA response regarding Alvotech's Biologics License Application for AVT05, the stock price dropped significantly. The firm encourages investors to choose experienced legal counsel for class actions.

The Nasdaq Biotechnology Index fell by 1.4%. Among the constituent stocks, 4D Molecular dropped by 13.13%, Zenas Biopharma fell by 11.64%, and Beam decreased by 9.49%. BioCryst Pharma rose by 5.75%, Erasca increased by 15.04%, and Immunitybio Inc. surged by 31.13%

Phibro Animal Health President and CEO Jack Bendheim Reports Sale of Common Shares

Jack Bendheim, President and CEO of Phibro Animal Health Corporation, reported the sale of common shares by multiple reporting owners, including himself. The full filing is accessible through a provided link. This news brief is generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

Acme United Corporation Acquires the Assets of My Medic | ACU Stock News

Acme United Corporation has acquired the assets of My Medic for $18.7 million, with an initial payment of $14.6 million. My Medic, a supplier of tactical and emergency response products, generated approximately $19 million in revenue in 2025. Acme United plans to enhance My Medic's operations and expand its product offerings in the U.S. and Canada. The acquisition is expected to leverage the combined marketing and distribution capabilities of both companies. The remaining purchase price includes contingent payments based on revenue milestones and indemnification claims.

EXCLUSIVE-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

The U.S. FDA has delayed reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin due to safety and efficacy concerns, including a patient death linked to Tzield. The review for Tzield has been postponed by over a month, while bitopertin's review is delayed by two weeks. The FDA's new fast-track program, aimed at expediting drug approvals, has faced scrutiny as several drugs have experienced significant delays. Experts express concern over the program's potential politicization and the rigorousness of reviews.